Codexis, Inc. (CDXS)
Codexis, Inc. specializes in discovering, developing, and selling enzymes and other proteins. Their CodeEvolver technology platform enhances manufacturing processes and enables novel biotherapeutic drug discovery.
Company Overview
Codexis is revolutionizing enzyme engineering with its CodeEvolver platform, enabling efficient biocatalyst development for pharmaceuticals and industrial applications, offering a compelling investment in sustainable and high-performance solutions within the biotechnology sector, despite current profitability challenges.
Investment Thesis
Investing in Codexis presents a unique opportunity to capitalize on the growing demand for sustainable and efficient manufacturing processes. The company's CodeEvolver platform provides a competitive edge in the enzyme engineering space, enabling the development of high-performance biocatalysts. While the company currently operates with a negative profit margin of -120.8%, the gross margin of 79.3% indicates the potential for significant profitability as the company scales its operations and reduces costs. Key growth catalysts include expanding partnerships with pharmaceutical companies and penetrating new markets for industrial biocatalysts. The high beta of 2.47 suggests significant volatility, but also the potential for substantial returns.
Key Highlights
- Market capitalization of $0.12 billion, reflecting the company's current valuation in the biotechnology market.
- Negative P/E ratio of -1.88, indicating that the company is currently not profitable.
- Gross margin of 79.3%, demonstrating the potential for profitability as the company scales its operations.
- Beta of 2.47, indicating higher volatility compared to the market, but also the potential for higher returns.
- No dividend yield, as the company is currently reinvesting its earnings for growth.
Competitors
Strengths
- Proprietary CodeEvolver technology platform.
- Expertise in enzyme engineering and biocatalysis.
- Strong relationships with pharmaceutical companies.
- High gross margin (79.3%) indicating pricing power.
Weaknesses
- Currently unprofitable with a negative P/E ratio.
- High beta indicating significant volatility.
- Reliance on a limited number of key customers.
- Limited geographic reach.
Catalysts
- Ongoing: Expansion of partnerships with pharmaceutical companies for drug manufacturing.
- Ongoing: Penetration of new markets for industrial biocatalysts.
- Upcoming: Potential FDA approval of biotherapeutic drug candidates developed using CodeEvolver.
- Ongoing: Licensing agreements for the CodeEvolver technology platform.
- Upcoming: New product launches in the molecular biology and in vitro diagnostics markets.
Risks
- Potential: Competition from other biotechnology companies with similar technologies.
- Potential: Technological obsolescence of the CodeEvolver platform.
- Ongoing: Regulatory hurdles in the pharmaceutical and industrial sectors.
- Potential: Economic downturn impacting demand for biocatalyst products and services.
- Ongoing: Dependence on key customers for a significant portion of revenue.
Growth Opportunities
- Expansion of Biotherapeutic Drug Discovery: Codexis can leverage its CodeEvolver platform to discover and develop novel biotherapeutic drug candidates for targeted human diseases. The market for biotherapeutics is rapidly growing, with a global market size projected to reach hundreds of billions of dollars. By partnering with pharmaceutical companies, Codexis can generate significant revenue streams through licensing agreements and royalties. This represents a long-term growth opportunity with substantial potential.
- Penetration of New Markets for Industrial Biocatalysts: Codexis can expand its reach into new markets for industrial biocatalysts, such as food and beverage, agriculture, and biofuels. These markets offer significant growth potential, as companies seek to adopt more sustainable and efficient manufacturing processes. By developing customized biocatalytic solutions for specific applications, Codexis can capture a significant share of these markets. This is an ongoing opportunity with continuous market expansion.
- Strategic Partnerships with Pharmaceutical Companies: Codexis can forge strategic partnerships with pharmaceutical companies to develop and commercialize biocatalytic processes for drug manufacturing. These partnerships can provide Codexis with access to new markets, funding, and expertise. By collaborating with established pharmaceutical companies, Codexis can accelerate the development and commercialization of its biocatalytic technologies. This is an ongoing opportunity as pharmaceutical companies seek more efficient manufacturing processes.
- Development of Novel Molecular Biology and In Vitro Diagnostic Enzymes: Codexis can develop novel molecular biology and in vitro diagnostic enzymes for use in research and clinical applications. The market for these enzymes is growing rapidly, driven by advancements in genomics and personalized medicine. By developing high-performance enzymes with unique properties, Codexis can capture a significant share of this market. This is an upcoming opportunity with continuous innovation in the diagnostics field.
- Licensing of CodeEvolver Technology Platform: Codexis can license its CodeEvolver technology platform to other companies, allowing them to develop their own biocatalytic solutions. This can generate a recurring revenue stream for Codexis and expand the reach of its technology. By licensing its platform, Codexis can leverage the expertise of other companies to develop new applications for its technology. This is an ongoing opportunity with potential for widespread adoption.
Opportunities
- Expansion into new markets for industrial biocatalysts.
- Development of novel biotherapeutic drug candidates.
- Strategic partnerships with pharmaceutical companies.
- Licensing of CodeEvolver technology platform.
Threats
- Competition from other biotechnology companies.
- Technological obsolescence.
- Regulatory hurdles.
- Economic downturn.
Competitive Advantages
- Proprietary CodeEvolver protein engineering platform.
- Expertise in enzyme engineering and biocatalysis.
- Strong relationships with pharmaceutical companies.
- Portfolio of biocatalyst products and services.
About
Codexis, Inc., founded in 2002 and headquartered in Redwood City, California, is a biotechnology company focused on discovering, developing, and selling enzymes and other proteins. The company's core technology is its CodeEvolver protein engineering platform, which allows for the rapid development of highly optimized biocatalysts. These biocatalysts are used in a variety of applications, including pharmaceutical manufacturing, industrial processes, and molecular biology. Codexis offers a range of products and services, including biocatalyst products, intermediate chemicals, and biocatalyst screening kits. The company also provides protein engineering services to customers seeking to optimize their own biocatalytic processes. Codexis sells its products and services primarily to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Their CodeEvolver platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes, expanding their reach beyond industrial applications.
What They Do
- Discovers and develops enzymes and other proteins.
- Offers biocatalyst products and services for various industries.
- Provides intermediate chemicals for further chemical processing.
- Offers Codex biocatalyst panels and kits for chemistry screening.
- Provides biocatalyst screening and protein engineering services.
- Offers CodeEvolver protein engineering technology platform.
- Develops biotherapeutic drug candidates for targeted human diseases.
- Creates molecular biology and in vitro diagnostic enzymes.
Business Model
- Sells biocatalyst products and services to pharmaceutical and other industries.
- Generates revenue from intermediate chemicals used in chemical processing.
- Provides protein engineering services to customers.
- Licenses its CodeEvolver technology platform.
Industry Context
Codexis operates within the biotechnology industry, which is experiencing rapid growth driven by advancements in genomics, proteomics, and synthetic biology. The market for industrial enzymes is projected to reach billions of dollars in the coming years, fueled by increasing demand for sustainable and efficient manufacturing processes. Codexis competes with companies like Amyris (ARMP) and Intellia Therapeutics (IPHA), but differentiates itself through its proprietary CodeEvolver platform, which enables rapid and efficient enzyme engineering. The company is well-positioned to capitalize on the growing demand for biocatalysts in the pharmaceutical and industrial sectors.
Key Customers
- Pharmaceutical manufacturers in the United States and Europe.
- Companies in the chemical processing industry.
- Research institutions and universities.
- Companies in the food and beverage, agriculture, and biofuels industries.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $9M | -$20M | $0.00 |
| Q2 2025 | $15M | -$13M | $0.00 |
| Q1 2025 | $8M | -$21M | $0.00 |
| Q4 2024 | $21M | -$10M | $0.00 |
Source: Company filings
Chart & Info
Price Chart
Codexis, Inc. (CDXS) stock price: $1.17 (+0.00, +0.00%)
Why Bull
- •Recent insider buying suggests confidence in the company's future, indicating that key stakeholders believe in its potential.
- •Community sentiment has shifted positively, with discussions highlighting innovative product developments that could drive growth.
- •Analysts are noting a strong pipeline of upcoming projects that align with current market trends, attracting investor interest.
- •The overall market perception has improved, with increasing recognition of the company's role in a growing sector.
Why Bear
- •Some recent community discussions express skepticism about the company's ability to scale its operations effectively amid rising competition.
- •There are concerns regarding the sustainability of its recent innovations and whether they can translate into long-term profitability.
- •Insider selling has raised red flags for some investors, leading to questions about the company's short-term outlook.
- •Market sentiment remains cautious, with some analysts warning of potential headwinds that could impact future performance.
Latest News
-
Earnings Scheduled For November 6, 2025
benzinga · Nov 6, 2025
-
Earnings Scheduled For August 13, 2025
benzinga · Aug 13, 2025
-
Earnings Scheduled For May 14, 2025
benzinga · May 14, 2025
-
Stocks That Hit 52-Week Lows On Friday
benzinga · Oct 7, 2022
Technical Analysis
Rationale
AI-generated technical analysis for CDXS including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Codexis, Inc. (CDXS) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for CDXS.
Make a Prediction
Set your price target for Codexis, Inc. (CDXS), choose a timeframe, and track your prediction accuracy.
Current price: $1.17
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CDXS.
Price Targets
Wall Street price target analysis for CDXS.
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 2/100
Revenue declined -15.4% YoY, signaling shrinking demand or market headwinds.
-
Gross Margin 3/100
Gross margin of -20.2% is below average, suggesting thin margins and potential pricing pressure.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 3/100
Net insider selling of -$0.59M may indicate reduced confidence or routine diversification by executives.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates CDXS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Frequently Asked Questions
What does Codexis, Inc. do?
Codexis, Inc. is a biotechnology company that specializes in enzyme engineering. They use their proprietary CodeEvolver platform to develop high-performance biocatalysts for a variety of applications, including pharmaceutical manufacturing, industrial processes, and molecular biology. The company's products and services help customers improve the efficiency, sustainability, and cost-effectiveness of their manufacturing processes. Codexis aims to be a leader in the enzyme engineering space, providing innovative solutions to a wide range of industries.
Is CDXS stock a good buy?
CDXS stock presents a mixed investment profile. While the company's innovative CodeEvolver platform and high gross margin (79.3%) suggest strong potential, its current lack of profitability (negative P/E) and high beta (2.47) indicate significant risk. Investors should carefully consider the company's growth opportunities, such as expanding partnerships and penetrating new markets, against the potential risks of competition and technological obsolescence. A long-term investment horizon may be necessary to realize the full potential of CDXS stock.
What are the main risks for CDXS?
The main risks for CDXS include intense competition from other biotechnology companies, the potential for technological obsolescence of its CodeEvolver platform, and regulatory hurdles in the pharmaceutical and industrial sectors. The company's high beta also indicates significant volatility, which could lead to substantial losses for investors. Additionally, an economic downturn could negatively impact demand for its biocatalyst products and services. Investors should carefully assess these risks before investing in CDXS stock.
Is CDXS a good stock to buy?
Whether CDXS is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the CDXS MoonshotScore?
The MoonshotScore for CDXS is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is CDXS data updated?
CDXS stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to CDXS is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for CDXS?
Growth catalysts for Codexis, Inc. (CDXS) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Codexis, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are CDXS's main competitors?
Codexis, Inc. (CDXS) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether CDXS has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about CDXS?
Wall Street analyst coverage for CDXS includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is CDXS's market cap?
Market capitalization (market cap) for CDXS is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows CDXS's current market cap alongside enterprise value and other valuation metrics.
How has CDXS stock performed recently?
CDXS's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing CDXS's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in CDXS?
Key risk categories for CDXS include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures CDXS's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling CDXS?
Insider trading activity for CDXS tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is CDXS a good stock for beginners?
Codexis, Inc. (CDXS) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is CDXS for first-time investors?
Every stock carries risk, including Codexis, Inc. (CDXS). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like CDXS.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Financial data is based on the most recent available information. Future performance is subject to market conditions and company-specific factors.